Top entities: Molecular Partners, United States — National Cancer Institute, Seth Lewis, Laura Jeanbart, Orano.

What category does this event fall under?

Tech — classified as conference presentations.

What is the sentiment of coverage?

Aggregate sentiment score: 20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Molecular Partners will present United States — National Cancer Institute · Molecular Partners announced attendance

Is this event still developing?

This is an active story, last updated May 04, 2026. Coverage continues to evolve.

Tech conference presentations

Molecular Partners Presents MP0712 at Conferences

Q: When did this event occur?

First reported May 04, 2026; last updated May 04, 2026.

Q: What is the market impact?

Direct. The market may react positively to the increased visibility of Molecular Partners AG's lead candidate MP0712 through these presentations, potentially leading to a short-term increase in its stock price.

Analysis based on 7 articles · First reported May 04, 2026 · Last updated May 04, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The market may react positively to the increased visibility of Molecular Partners AG's lead candidate MP0712 through these presentations, potentially leading to a short-term increase in its stock price. The presentations could highlight the potential of DARPin therapeutics, attracting investor interest in the biotechnology sector.

Biotechnology Pharmaceuticals

Event Summary

Molecular Partners AG, a clinical-stage biotech company, announced its attendance and presentations at several upcoming scientific conferences in May 2026. The company will present on its lead Radio-DARPin candidate MP0712, a ²¹²Pb-based candidate for targeted anti-DLL3 radiotherapy of small cell lung cancer (SCLC). Presentations are scheduled for the NIH United States — National Cancer Institute 2026 Small Cell Lung Cancer Consortium Meeting, the 22nd Annual PEGS Boston, and Antibody & Engineering Therapeutics. These presentations aim to share molecular characteristics, preclinical insights, clinical development progress, and first-in-human insights for MP0712 and future DARPin candidates.

Key Actions

80 Molecular Partners will present United States — National Cancer Institute

70 Molecular Partners announced attendance

Entities Involved

stock

Molecular Partners

Molecular Partners AG is presenting its lead Radio-DARPin candidate MP0712 at multiple scientific conferences, which could increase visibility and investor interest in its DARPin therapeutics.

Importance 100 Sentiment 20

govactor

United States — National Cancer Institute

The United States — National Cancer Institute is hosting the 2026 Small Cell Lung Cancer Consortium Meeting where Molecular Partners AG will present on MP0712.

Importance 20 Sentiment 0

per

Seth Lewis

Seth Lewis is the EVP Corporate Finance for Molecular Partners AG and is listed as a contact for further details regarding the company's presentations.

Importance 10 Sentiment 0

per

Laura Jeanbart

Laura Jeanbart is the Head of Portfolio Management & Communications for Molecular Partners AG and is listed as a contact for further details regarding the company's presentations.

Importance 10 Sentiment 0

priv

Orano

Molecular Partners AG has a collaboration with Orano, which is mentioned in the forward-looking statements section as a potential source of benefits and results.

Importance 10 Sentiment 0

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard